Search

Search Results

• Book

  Adenosine receptors in neurodegenerative diseases

  edited by David Blum, Luísa V. Lopes.

  Contents:
  Adenosine receptor biology in the central nervous system / Michael Freissmuth and Karl-Norbert Klotz
  Adenosine signaling throughout development / Stefania Zappettini and Christophe Bernard
  Influence of adenosine on synaptic excitability / Detlev Boison, Raquel B. Dias, Traci Plumb, Sofia Cristóvão-Ferreira and Ana M. Sebastião
  Regulation of synaptic transmission by adenosine at the neuromuscular junction / Paula Pousinha and Joaquim A. Ribeiro
  Gene regulation of adenosine A₂a receptors in the central nervous system
  Sleep, adenosine, and neurodegeneration / Theresa E. Bjorness and Robert W. Greene
  National vs glial cell contribution to adenosine A₂a receptor-induced neurodegeneration / Antonella Ferrante, Maria T. Tebano, Alberto Martire, Maria R. Domenici and Patrizia Popoli
  Adenosine and oxygen/glucose deprivation in the brain / Felicita Pedata, Ilaria Dettori, Irene Fusco, Elisabetta Coppi, Anna M. Pugliese and Alessia Melani
  Adenosine receptors and memory disorders / Alexandre De Mendonca, David Blum and Jonathan D. Geiger
  Control of motor function by adenosine A₂a receptors in Parkinson's and Huntington's disease / Annalisa Pinna, Jadwiga Wardas, Maria R. Domenici, Patrizia Popoli, Giovanni Cossu and Micaela Morelli
  Adenosine receptors oligomers in Parkinson's disease / Víctor Fernández-Dueñas and Francisco Ciruela
  Adenosine control of striatal function / Sergi Ferré.

  Digital Access ScienceDirect 2017
  Get Shareable Link

  View Details
• Article

  Doppelblindvergleich von Vincamin gegen Plazebo bei Patienten mit Innenohrschwerhörigkeit. [Double-blind comparison of vincamine and placebo in patients with presbyacusis (author's transl)].

  Reinecke M.

  Arzneimittelforschung. 1977;27(6a):1294-8.

  14-15-Dihydro-14beta-hydroxy-[3alpha,16alpha]-eburnamenine-14-carbonic acid methylester (vincamine, Vincapront) and placebo were compared in a double-blind trial, using daily doses of 60 mg p.o. in 30 out-patients suffering from peripheral and mainly centrally induced labyrinthine deafness (presbyacusis). The treatment lasted for 6 weeks. The diagnosis was established by otological examinations, the SISI test and pure-tone and speech audiometry. Other causes of disease were excluded. 6 patients suffered from an accompanying disease needing treatment (glycosides, antihypertensives). 1 patient had an intercurrent rhinopharyngitis. Any other drug was discontinued at the beginning of treatment. The result was checked by pure-tone and speech audiometry (monosyllabic word test) before and after treatment. The pure-tone audiometric test did not reveal any change in both groups while speech audiometry (monosyllabic word test) showed significant improvements in the vincamine group (p less than 0.004). Only random alterations occurred in the control group. Vincamine was well tolerated by all patients. The tolerance of placebo was rated to be moderate by two patients.

  Digital Access Access Options
  Get Shareable Link

  PubMed